Evidence map›Paper›PMID 26599087›Full record

ArticlePloS one2015

Antimicrobial Activity of a Novel Vascular Access Film Dressing Containing Chlorhexidine Gluconate.

Anne Wibaux, Priyaleela Thota, Jozef Mastej, Daniel L Prince, Neal Carty, Peter Johnson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Anne WibauxVancive Medical Technologies, an Avery Dennison business, 20 N. Wacker Drive Suite 2240, Chicago, Illinois, 60606, United States of America.
Priyaleela ThotaVancive Medical Technologies, an Avery Dennison business, 20 N. Wacker Drive Suite 2240, Chicago, Illinois, 60606, United States of America.
Jozef MastejGibraltar Laboratories Inc., Fairfield, New Jersey, 07004, United States of America.
Daniel L PrinceGibraltar Laboratories Inc., Fairfield, New Jersey, 07004, United States of America.
Neal CartyVancive Medical Technologies, an Avery Dennison business, 20 N. Wacker Drive Suite 2240, Chicago, Illinois, 60606, United States of America.
Peter JohnsonVancive Medical Technologies, an Avery Dennison business, 20 N. Wacker Drive Suite 2240, Chicago, Illinois, 60606, United States of America.
Avery Dennison (United States) · USGibraltar Health Authority · GI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCovering insertion sites with chlorhexidine impregnated dressings has been proven to be clinically effective in reducing catheter related blood stream infections (CR-BSI). Two chlorhexidine gluconate (CHG)-impregnated dressings are commercially available, a polyurethane foam disk and a film dressing containing a chlorhexidine gluconate-impregnated gel pad. While both have demonstrated efficacy in clinical settings, the major drawback of high cost and impaired IV insertion site visibility limits their usage. A new, simple film dressing containing CHG within its adhesive layer is now available. The objective of this study was to test the in vitro antimicrobial efficacy of the new dressing in comparison to the CHG-impregnated gel dressing.

methodsQuantitative aliquots of suspensions (concentration of 1.0x106 to 5.0x106 cfu/sample) of clinically relevant challenge organisms (Staphylococcus species, gram-negative bacilli, Candida albicans) were incubated in contact with the new CHG-containing film dressing, a placebo version of the same (negative control) and the commercially available CHG-impregnated gel dressing (positive control). Serial dilutions of the surviving organisms were quantified using the pour plate after 1, 3, 5, and 7 days of incubation in order to calculate an antimicrobial log10 reduction for each organism/dressing combination at each point in time.

resultsThe new CHG-containing film dressing delivered greater than 5.0 log10 reduction throughout the 7 days on all aerobic gram-negative bacilli and Staphylococcus species tested. As of day 1 the CHG-containing film dressing provided greater than 5.0 log10 reduction on Candida albicans. There were no statistically significant differences in the log10 reduction between the two dressings tested.

conclusionThe new CHG-containing film dressing was found to be as effective as the chlorhexidine gluconate-impregnated gel dressing on clinically relevant microbes.

Indexed as

BandagesAdhesivesAnti-Infective AgentsCandida albicansCatheter-Related InfectionsChlorhexidineHumansPolyurethanesStaphylococcusWound Closure TechniquesAdhesivesAnti-Infective AgentsChlorhexidinechlorhexidine gluconatepolyurethane foamPolyurethanes

Identifiers

PMID26599087
PMCPMC4657924
OpenAlexW2173893537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.